Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.0173 | 1 | 1 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.2551 | 0.2551 |
Loa Loa (eye worm) | hypothetical protein | 0.0028 | 0.0795 | 0.1789 |
Schistosoma mansoni | jun-related protein | 0.0071 | 0.3557 | 0.2976 |
Trichomonas vaginalis | dihydropyrimidine dehydrogenase, putative | 0.0067 | 0.3323 | 0.5 |
Echinococcus multilocularis | dihydropyrimidine dehydrogenase (NADP+) | 0.0067 | 0.3323 | 0.6618 |
Schistosoma mansoni | dihydroorotate dehydrogenase | 0.0173 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0028 | 0.0828 | 0.1862 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.0067 | 0.3323 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0071 | 0.3557 | 0.2976 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.0173 | 1 | 1 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.0067 | 0.3323 | 0.5 |
Entamoeba histolytica | dihydropyrimidine dehydrogenase, putative | 0.0067 | 0.3323 | 0.5 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.0067 | 0.3323 | 0.5 |
Mycobacterium leprae | Probable dihydroorotate dehydrogenase PyrD | 0.0173 | 1 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0087 | 0.4597 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.2551 | 0.574 |
Loa Loa (eye worm) | hypothetical protein | 0.0028 | 0.0828 | 0.1862 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.0067 | 0.3323 | 0.5 |
Trichomonas vaginalis | dihydroorotate dehydrogenase, putative | 0.0067 | 0.3323 | 0.5 |
Echinococcus granulosus | dihydropyrimidine dehydrogenase NADP | 0.0067 | 0.3323 | 0.6618 |
Brugia malayi | intermediate filament protein | 0.0028 | 0.0828 | 0.0828 |
Echinococcus multilocularis | jun protein | 0.0087 | 0.4597 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.2551 | 0.1879 |
Trypanosoma cruzi | dihydroorotate dehydrogenase, putative | 0.0173 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0069 | 0.3405 | 0.3405 |
Trypanosoma cruzi | dihydroorotate dehydrogenase (fumarate), putative | 0.0173 | 1 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0028 | 0.0828 | 0.0828 |
Leishmania major | dihydroorotate dehydrogenase | 0.0173 | 1 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.2551 | 0.1879 |
Brugia malayi | Zinc finger, C2H2 type family protein | 0.0067 | 0.3323 | 0.3323 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.2551 | 0.4572 |
Mycobacterium tuberculosis | Probable dihydroorotate dehydrogenase PyrD | 0.0173 | 1 | 0.5 |
Brugia malayi | bZIP transcription factor family protein | 0.0087 | 0.4597 | 0.4597 |
Echinococcus multilocularis | dihydropyrimidine dehydrogenase (NADP+) | 0.0067 | 0.3323 | 0.6618 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0087 | 0.4597 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.2551 | 0.4572 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.4445 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.2551 | 0.4572 |
Loa Loa (eye worm) | intermediate filament protein | 0.0028 | 0.0828 | 0.1862 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.2551 | 0.4572 |
Trypanosoma brucei | dihydroorotate dehydrogenase (fumarate) | 0.0173 | 1 | 0.5 |
Plasmodium falciparum | dihydroorotate dehydrogenase | 0.0173 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | dihydroorotate dehydrogenase 2 | 0.0173 | 1 | 0.5 |
Mycobacterium ulcerans | dihydroorotate dehydrogenase 2 | 0.0173 | 1 | 0.5 |
Toxoplasma gondii | dihydroorotate dehydrogenase reveal, putative | 0.0173 | 1 | 0.5 |
Echinococcus granulosus | jun protein | 0.0087 | 0.4597 | 1 |
Onchocerca volvulus | 0.0069 | 0.3405 | 1 | |
Plasmodium vivax | dihydroorotate dehydrogenase, mitochondrial precursor, putative | 0.0173 | 1 | 0.5 |
Echinococcus granulosus | dihydropyrimidine dehydrogenase NADP | 0.0067 | 0.3323 | 0.6618 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.2551 | 0.1879 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.7943 uM | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.